 Connection
Robert Lentz to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Robert Lentz has written about Antineoplastic Combined Chemotherapy Protocols.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.559 |
|
|
|
-
Lentz RW, Friedrich TJ, Blatchford PJ, Jordan KR, Pitts TM, Robinson HR, Davis SL, Kim SS, Leal AD, Lee MR, Waring MRN, Martin AC, Dominguez ATA, Bagby SM, Hartman SJ, Eckhardt SG, Messersmith WA, Lieu CH. A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer. Clin Cancer Res. 2024 Sep 03; 30(17):3768-3778.
Score: 0.497
-
Ueberroth BE, Lieu CH, Lentz RW. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation. J Gastrointest Cancer. 2024 Sep; 55(3):1448-1452.
Score: 0.488
-
Robinson HR, Messersmith WA, Lentz RW. HER2-Positive Metastatic Colorectal Cancer. Curr Treat Options Oncol. 2024 05; 25(5):585-604.
Score: 0.482
-
Davis AA, Iams WT, Chan D, Oh MS, Lentz RW, Peterman N, Robertson A, Shah A, Srivas R, Wilson TJ, Lambert NJ, George PS, Wong B, Wood HW, Close JC, Tezcan A, Nesmith K, Tezcan H, Chae YK. Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors. Mol Cancer Ther. 2020 07; 19(7):1486-1496.
Score: 0.092
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|